Obudai Egeszseguegyi Centrum Kft.
- Address
- Ground Floor 1 Door, Arany Janos Ter 2, 7400 Kaposvár, Hungary
Cardiovascular Diseases
Obudai Egeszseguegyi Centrum Kft. is focusing on atherosclerotic cardiovascular disease, investigating new therapies to lower heart risk and improve outcomes for patients with heart and blood vessel conditions, including the use of agents such as inclisiran aimed at reducing major adverse cardiovascular events.
- Atherosclerotic cardiovascular disease (ASCVD)
- Atrial fibrillation
- Hyperlipidemia and LDL‑C reduction
- Primary prevention of cardiovascular events
- Renal‑cardiac risk management in chronic kidney disease
The site’s multidisciplinary team collaborates with European research networks to advance heart‑health therapies.
Immune System Diseases
Research at the centre addresses autoimmune disorders, testing biologic agents that aim to control inflammation and restore joint function in conditions such as rheumatoid arthritis and psoriatic arthritis, with compounds like sonelokimab under evaluation.
- Moderate to severe rheumatoid arthritis
- Active psoriatic arthritis
- Biologic‑naïve and biologic‑experienced patient cohorts
- Evaluation of ACR50 response
- Safety of subcutaneous biologics
These studies are conducted under the oversight of experienced rheumatology investigators at Obudai Egeszseguegyi Centrum.
Nutritional and Metabolic Diseases
The centre evaluates metabolic therapies targeting weight management, lipid disorders, and kidney‑related hypertension, including trials in patients with obesity and agents such as retatrutide for cardiovascular benefit, as well as studies on hypertriglyceridemia.
- Obesity with established cardiovascular disease
- Severe hypertriglyceridemia
- Hyperlipidemia and LDL‑C lowering
- Combination of baxdrostat with dapagliflozin in CKD
- Metabolic risk reduction in high‑risk patients
Patients are recruited locally and across Hungary, providing valuable data for European metabolic research.
Skin and Connective Tissue Diseases
Investigations include skin‑related autoimmune conditions, focusing on novel agents that aim to heal chronic wounds and control joint inflammation, such as therapies for chronic venous ulcers and the use of sonelokimab in psoriatic arthritis.
- Therapy‑resistant chronic venous ulcers
- Active psoriatic arthritis in biologic‑naïve patients
- Evaluation of wound closure rates
- Safety of topical stem‑cell therapy
- Impact on quality of life for skin disease patients
Obudai Egeszseguegyi Centrum leverages its dermatology expertise to bring innovative treatments to patients in Kaposvar.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Anthos Therapeutics Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Obudai Egeszseguegyi Centrum Kft.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimilar (DRL_Tocilizumab) with tocilizumab reference product (RoActemra®) administered by the subcutaneous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis | Dr Reddy's Laboratories Limited | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 2 | Unknown | 2023-09-04 | 2023-09-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.